James Lucocq
@jameslucocq
Followers
92
Following
48
Media
0
Statuses
27
Surgical Registrar, BJS, BJS institute, RAMC, MFAC, MRBS Student, Medical Xcelerator
Scotland, United Kingdom
Joined January 2020
Epidemiological data on Acute Pancreatitis admissions (2013-2023) in England 🏴 @hpbjournal ➡️Incidence of AP 456 cases/mill ➡️Annual increase of 2.6 % ⬆️ ➡️ITU Admission 8% ➡️In-hospital mortality 4.5% ➡️ OS at 1, 5,10 y :88%,75% 63% ➡️ Northeast England ⬆️ @jameslucocq
1
11
39
Pleased to share our latest paper showing socioeconomic deprivation does not adversely affect outcomes of bariatric surgery. https://t.co/9FMgNI2BOs
@bariatricBOMSS @EdinSurg @JournalObesity @gilliandRD @BariatricBrian @jameslucocq @acdebeaux @GeorgiosGeropo1
1
2
7
🔪 Open 🔦 Laparoscopic 🤖 Robot Pancreatoduodenectomy Randomised Controlled Trials 🧮 Network Meta-Analysis on 7 RCT 1.3 K patients 🔦 LPD ⬇️ LOS and blood loss vs. OPD 🔪 OPD ⬇️ OR time vs. LPD 🤖 RPD similar OPD but data preliminary.. 🫵 Surprised? https://t.co/5smPthSlYx
1
23
60
The E-AHPBA Scientific & Research Committee is pleased to endorse the ADENO-IPMN 2 Study with a Blue Seal of Approval! 💙 Register your centre's participation here: https://t.co/s9ADVy3lCy
@sanjay_HPB @jameslucocq
#EAHPBA #ScientificResearch #IPMN #Adenocarcinoma
docs.google.com
The present study aims to determine the impact of contemporary neoadjuvant, adjuvant and palliative chemotherapy regimens on recurrence and survival outcomes in resectable, borderline resectable,...
0
7
10
#Editorial @BJSurgery on Adenoca arising from IPMN #AIPMN study 459🧑🏻🤝🧑🏻 👉 5y DFS 30% 👉Rx of recurrence ⬆️ Survival 👉AdjChemo⛔impact 👉Gastric/PBtypes⬇️prognosis 👉Survival related to invasive type than precursor 👉10y OS A-IPMN 35% PDAC 9% @jameslucocq
https://t.co/zRj6CMCz8d
2
15
47
👉🌎 on analgesic use in AP https://t.co/Z0uTffzx9A👉 1864 🧑🤝🧑 118 centres & 27 countries 👉 Opioid use⬇️in Europe and ⬆️ Asia and AUS 👉 Pain severity, long pain duration, ANC, WON ⬆️ opioid use at discharge @my_ueg guidelines ✍️ underway https://t.co/OEB3NpCoSj
@CSKnoph
1
11
32
👉🌎study on Precursor Epithelial types of MalignantIPMN and recurrence/survival after🗡️ 297 🧑🤝🧑 👉 Gastric, PB, mixed🧑🤝🧑same clinicopath but ⬇️outcomes than intestinal 👉⏰to recurrence👍intestinal type 👉 Adj chemo⬆️survival in PB type https://t.co/gLw1mkCTjg
@jameslucocq
0
17
33
Multicenter study🌎on Long term survival after 🗡️ malignant IPMN 👉288 pts 98 m FU 👉48% recurrence with⬆️systemic recurrence 👉5y OS 46% 👉5y DFS 35% 👉Multivisceral resection, tail location , LVI, PNI⬇️long-term DFS @jameslucocq @SurgJournal
https://t.co/U8CT4p1LSf
1
15
27
Great to see @jameslucocq and @joseph_nejo give their oral presentations at @IHPBA Cape Town including one in best of the best section. Thanks again to all collaborators for the data #ipmn #adenoipmn
#collaborative
0
7
32
🌎Multicenter study on Adj chemo (AC) 💊 for adenocarcinoma in IPMN 👉 18 centers & 469 patients 60% ✅AC 👉 78 m follow up 👎AC no impact on recurrence DFS OS 👎 No benefit in high risk groups 💊 No chemo regimen superior @jameslucocq @BJSurgery
https://t.co/O9csMN9dZf
2
23
51
Great work @sanjay_HPB and team 👇🏻@AnnalsofSurgery @hpb_so @P_C_E_ Pointing to biological differences and outcomes , more to come 🤩👍🏻
➡️Long term outcomes PDAC versus A-IPMN ➡️18 centres 476 PDAC vs 459 A-IPMN patients ➡️Median survival Survival PDAC 19m vs 39 m ⏱️to recurrence for 15 vs 33 m 📈10 y survival 9% vs 34% ➡️Adj Chemo⬆️survival PDAC. No impact A-IPMN https://t.co/qSKgp0O3dH
0
8
22
➡️Long term outcomes PDAC versus A-IPMN ➡️18 centres 476 PDAC vs 459 A-IPMN patients ➡️Median survival Survival PDAC 19m vs 39 m ⏱️to recurrence for 15 vs 33 m 📈10 y survival 9% vs 34% ➡️Adj Chemo⬆️survival PDAC. No impact A-IPMN https://t.co/qSKgp0O3dH
1
26
56
👉🏾Prospective study on PROMs and QOL after PD at 5 time points 👉🏾Adj Chemo and post-op complications did not affect QoL 👉🏾General QoL and health were PROMs rated as ‘very important' 👉🏾QoL measures return to baseline at 6-months postop @hpbjournal
https://t.co/P8E0sg7iB3
0
12
33
The value of Transvesical-assisted cystic pedicle dissection. A large stone appearing at ? Hartman Pouch, ? GB neck. 1- never dissect proximal to stone 2- never assume it is in HP 3- immediately suspect Mirizzi 4- accessing the stone through the GB will help either transvesical
7
27
129
👉Recurrence patterns and Rx of Recurrence for Invasive #IPMN 🌏459patients 18 Pancreatic units ✅1y recurrence 23% Overall Recurrence 45% Median time to recurrence 33m ✅Adj chemo No impact on recurrence ✅Rx of recurrence⤴️survival @AnnalsofSurgery
https://t.co/p33o1nLi5y
6
31
83
Risk of Recurrence > Surgical Resection for Adenocarcinoma Arising from IPMN: International Multicentre Observational Study 18centres 459patients #pancreaticcancer @AnnalsofSurgery @sanjay_HPB @ksoreide @grisurgery
pubmed.ncbi.nlm.nih.gov
Recurrence after pancreatic resection for adenocarcinoma arising from IPMN is frequent with a quarter of patients recurring within 12 months. Treatment of recurrence is associated with improved...
0
3
16
2100 patients with Acute Pancreatitis recruited into PAINAP study in 3 months !!! Potentially the largest study in literature dedicated to pain management in AP and very grateful to recruiting centers Recruitment now complete and moving onto data validation. @hpbnorth
2
10
33
Patient with acute gallstone pancreatitis, unfit for GA/ Lap Chole. MRCP - small stones in GB but no CBD stone. Do you proceed with ERCP and prophylactic sphincterotomy? Is there evidence that prevents recurrent pancreatitis?
6
1
7
Lower-Pressure Pneumoperitoneum Decreases Post-op Pain https://t.co/prQaohHgkw
@gensurgnews
0
8
15